An interim trial analysis for Oxford-AstraZeneca's COVID-19 vaccine found the candidate's average efficacy to be 70 percent. While considered encouraging, it falls short of the rates shown by Pfizer/BioNTech and Moderna, whose vaccines appear to be more than 90 percent effective.
Still, the Oxford-AstraZeneca candidate has a few key advantages — it can be stored at regular refrigerators temperatures for a long period of time, and it's much cheaper than the other candidates, which means it could be particularly crucial for developing nations and rural communities around the world.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
'Wonder drug': the potential health benefits of creatineThe Explainer Popular fitness supplement shows promise in easing symptoms of everything from depression to menopause and could even help prevent Alzheimer's
-
What's next for Elon Musk?Today's Big Question The world's richest man has become 'disillusioned' with politics – but returning to his tech empire presents its own challenges
-
Quiz of The Week: 24 – 30 MayHave you been paying attention to The Week's news?
-
RFK Jr. scraps Covid shots for pregnant women, kidsSpeed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sickspeed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last yearspeed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive orderspeed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measlesSpeed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study findsSpeed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
-
Measles outbreak spreads, as does RFK Jr.'s influenceSpeed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments
-
RFK Jr. offers alternative remedies as measles spreadsSpeed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
